Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | 177Lu-girentuximab |
| Trade Name | |
| Synonyms | 177Lu-DOTA-cG250|Lu-177 girentuximab|177Lu-TLX250|[177Lu]-TLX250 |
| Drug Descriptions |
177Lu-girentuximab is a radioconjugate comprising girentuximab (TLX250), a monoclonal antibody that targets CA9 (CAIX), conjugated to the radionuclide lutetium 177, which delivers radiation to tumor cells and potentially results in inhibition of tumor growth (PMID: 14960657, PMID: 22980441, PMID: 40227816). |
| DrugClasses | |
| CAS Registry Number | NA |
| NCIT ID | C66978 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| 177Lu-girentuximab | 177Lu-girentuximab | 0 | 1 |
| 177Lu-girentuximab + Cabozantinib + Nivolumab | 177Lu-girentuximab Cabozantinib Nivolumab | 0 | 1 |
| 177Lu-girentuximab + Nivolumab | 177Lu-girentuximab Nivolumab | 0 | 1 |
| 177Lu-girentuximab + Peposertib | 177Lu-girentuximab Peposertib | 0 | 1 |